Table 5.
Acute GI toxicities by treatment group
| Maximal GI toxicity | FL regimen |
CP regimen |
||||
|---|---|---|---|---|---|---|
| 3D group (n=47) | 2D group (n=39) | p-value | 3D group (n=51) | 2D group (n=21) | p-value | |
| During RT | 0.054 | 0.927 | ||||
| Grade 0 | 12 (25.5) | 6 (15.4) | 16 (31.4) | 7 (33.3) | ||
| Grade 1 | 24 (51.1) | 18 (46.1) | 28 (54.9) | 10 (47.6) | ||
| Grade 2 | 9 (19.1) | 11 (28.2) | 5 (9.8) | 3 (14.3) | ||
| Grade 3 or higher | 2 (4.3) | 4 (10.3) | 2 (3.9) | 1 (4.8) | ||
| 1-Month post-RT | 0.493 | 0.476 | ||||
| Grade 0 | 17 (36.2) | 13 (33.3) | 21 (41.2) | 8 (38.1) | ||
| Grade 1 | 26 (55.3) | 20 (51.3) | 27 (52.9) | 11 (52.4) | ||
| Grade 2 | 3 (6.4) | 4 (10.3) | 3 (5.9) | 1 (4.8) | ||
| Grade 3 or higher | 1 (2.1) | 2 (5.1) | - | 1 (4.8) | ||
GI, gastrointestinal; FL, intravenous fluorouracil and leucovorin; CP, oral capecitabine and cisplatin; 2D, 2-dimensional; 3D, 3-dimensional; RT, radiation therapy.